Complement C3 inhibitor

This page covers all Complement C3 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Complement C3, Complement component C3.

Targets

Complement C3 · Complement component C3

Marketed (1)

• Izervay™ · Hoffmann-La Roche · Ophthalmology
  Izervay is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage in retinal diseases.

Phase 3 pipeline (4)

• ALXN1850 · Alexion Pharmaceuticals, Inc. · Nephrology / Immunology
  ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases.
• ALXN2060 · Alexion Pharmaceuticals, Inc. · Immunology / Hematology
  ALXN2060 is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage.
• APL-2 · Apellis Pharmaceuticals, Inc. · Immunology
  APL-2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.
• APL-2, Pegcetacoplan · Apellis Pharmaceuticals, Inc. · Immunology / Rare Disease
  Pegcetacoplan is a complement C3 inhibitor that blocks the activation and amplification of the complement cascade by targeting C3.

Phase 2 pipeline (1)

• APL2 · Apellis Pharmaceuticals, Inc. · Immunology
  APL2 is a complement C3 inhibitor that blocks the central component of the complement cascade to reduce inflammation and tissue damage.